医学
累积发病率
置信区间
核医学
危险系数
入射(几何)
临床终点
辐照
随机对照试验
比例危险模型
统计显著性
放射科
泌尿科
乳腺癌
总体生存率
放射治疗
临床试验
相对风险
内科学
保乳手术
肿瘤科
作者
Bruno Meduri,A. Baldissera,Cinzia Iotti,Luc J.E.E. Scheijmans,Marcel R. Stam,Salvatore Parisi,Liesbeth Jorinne Boersma,Ilario Ammendolia,Eveline Koiter,Paola Canino,Dianne M. Busz,Marika C. Stenfert Kroese,Patrizia Giacobazzi,Maria Paola Ruggieri,Antoine M. Engelen,Tindara Munafò,Karolien Verhoeven,Mariacarla Valli,Roberto Vicini,Riccardo Cuoghi Costantini
摘要
PURPOSE: The aim of this study was to investigate whether external-beam accelerated partial-breast irradiation (APBI) provides noninferior local control compared with whole-breast irradiation (WBI). PATIENTS AND METHODS: We conducted this randomized phase III trial (ClinicalTrials.gov identifier: NCT01803958) in 35 centers. Patients age ≥49 years with invasive breast cancer, resection margins ≥2 mm, tumor diameter ≤3 cm, and pN0-1 were randomly assigned 1:1 to WBI or APBI (38.5 Gy in 10 fractions twice daily). Neither patients nor investigators were masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence (IBTR), analyzed according to the modified intention-to-treat analysis. We assumed a 5-year IBTR rate of 4% in the WBI group to exclude a 2% increase in the APBI group (90% power; noninferiority margin hazard ratio [HR], 1.5). RESULTS: Between 2007 and 2019, 3,309 patients were randomly assigned (1,652 to APBI, 1,657 to WBI); 84 were excluded from the analysis. The median follow-up was 97.5 months. The 5-year cumulative IBTR incidence was 1.0% (95% CI, 0.6 to 1.6) for APBI and 0.8% (95% CI, 0.5 to 1.4) for WBI. The HR for APBI versus WBI was 1.18 (90% CI, 0.63 to 2.20) with the upper confidence limit crossing the prespecified noninferiority margin. CONCLUSION: At 5 years, the cumulative incidence of IBTR is exceptionally low (≤1%) in both arms. Although formal statistical noninferiority was not demonstrated because the upper confidence limit crossed the margin, the absolute difference was <0.2%. External-beam APBI therefore is a reasonable clinical alternative to WBI for low-risk patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI